BUZZ-Relmada Therapeutics explores strategic options; shares up

Reuters
2024-12-09

** Shares of drug developer Relmada Therapeutics rise 4.9% to 48 cents

** Co says it has commenced a process to explore strategic alternatives after discontinuing two late-stage studies planned for the development of its depression drug

** Co plans to consider a wide range of options including sale of company assets, a sale of the company, a merger or a reverse merger; adds it has not set a timetable for completion of the evaluation process

** Says co is in the process of engaging a financial advisor to assist in the strategic review process

** The stock fell more than 70% last week after the company said its depression drug, esmethadone, was "unlikely" to meet the main goal of a late-stage trial

** Including session moves, stock down 88.4% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10